Eli Lilly 4Q profit slips but tops expectations

Published



INDIANAPOLIS (AP) — Eli Lilly and Co.’s fourth quarter earnings slipped 4 percent as generic competition continued to eat away at sales of its former best-seller, the antipsychotic Zyprexa, but the drugmaker cut expenses again and growth from other products helped it beat analyst expectations.

It also raised its forecast for 2013, and its shares edged up in premarket trading.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.